SINOMAB

中國抗體製藥有限公司
SinoMab BioScience Limited
(Incorporated in Hong Kong with limited liability)

Stock Code: 3681

2020 Annual Results

Quick Glance at SinoMab

- **First Hong Kong-based listed biopharmaceutical company** dedicated to the research, development, manufacturing and commercialisation of therapeutics for the **treatment of immunological diseases**
- Focuses on therapeutics for the **treatment of immunological diseases** including Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and asthma
- R&D base in Hongkong, Production base in mainland China
- Vision: to become a **global leader** in the **innovation of therapeutics for immunological diseases**

01 Business Highlights

Our Pipeline

Pipeline	Indication	Territory	IND Enabling Stage I	IND Enabling Stage II	IND Enabling Stage III	Phase I	Phase II	Phase III
SM03 (anti-CD22) (First-in-Target)	Rheumatoid arthritis (RA)	China						
	Non-Hodgkin's lymphoma (NHL)							
	Systemic lupus erythematosus (SLE)							
	Sjogren's syndrome (SS)							
SN1011 (BTK Inhibitor) (Third-Generation)	Systemic lupus erythematosus (SLE)	China						
	Rheumatoid arthritis (RA)							
	Rheumatoid arthritis (RA)	Australia						
	Systemic lupus erythematosus (SLE)							
	Pemphigus							
SM17 (Humanised Anti-IL17RB) (First-in-Class & First-in-Target)	Asthma							
	Idiopathic Pulmonary fibrosis (IPF)							
SM06 (Humanised anti-CD22)	Systemic lupus erythematosus (SLE)							
	Rheumatoid arthritis (RA)							
	Sjogren's syndrome (SS)							
SM09 (Humanised anti-CD20)	Non-Hodgkin's lymphoma (NHL)							
	Rheumatoid arthritis (RA)							
TNF2 (Humanised Ab)	Rheumatoid arthritis (RA)							

Clinical stage IND enabling stage

Flagship Product SM03
First-in-target Anti-CD22 mAb

- As of the end of 2020, 332 patients have been enrolled into SM03 Phase III clinical trials for RA, and safety data of interim analysis were generally in line with those in Phase II trials
- Plan to file Biologics Licence Application (BLA) with the NMPA as soon as the second half of 2021
- Negate the previously planned bridging clinical study in Australia due to the plan to file IND application in the US for SM06
- Expect to initiate Phase II clinical study for SLE in the second half of 2021 and **commercialise SM03 by the end of 2021 at the earliest**

Key Product SN1011
3rd Generation Covalent Reversible BTK Inhibitor

- Currently in Phase I clinical trial in Australia, evaluating safety and tolerability; as of 15 January, single ascending dose (SAD) study has been completed on 40 subjects
- Filed an IND application to the NMPA on 22 June 2020, accepted on 25 June 2020 and approved on 27 August 2020
- On 15 January 2021, first healthy subject was successfully dosed in Phase I clinical trial in Shanghai; as of the date of results announcement, 27 subjects have been enrolled into Phase I clinical trial
- Expect to complete Phase I clinical study in the first half of 2021 and **initiate Phase II clinical study for SLE in the second half of 2021**

Key Product SM17
Anti-IL17RB Antibody

- Generating and collecting necessary data for IND filing; production process development is completed, and clinical batch for Phase I trials is now under manufacturing
- Compiling the dossier for IND filing globally by the second half of 2021, and now conducting in-house proof-of-concept (POC) studies
- **Intend to enter into human clinical trials by the first quarter of 2021**

Other Drug Candidates

SM06 Humanised Anti-CD22

Currently optimising production and speeding up the filing for clinical studies in the US, with an expected timeframe speeded up to 2 years

To engage regulatory authorities to initiate clinical trials of SM06 once SM03 is commercialised

SM09 Humanised Anti-CD20

Continue to optimise production and expect to complete pre-clinical research in 2 years

TNF2 Humanised Anti-TNF-α

Production cell lines, cell banks and manufacturing process have been established

Optimising production and expect to complete pre-clinical research in 2 years

Our Production Base

Suzhou Production Base

Currently under commissioning, with an area of **7,000 sq.m** and a planned production capacity of **6,000L**

Administrative arm has been in operation since **late 2020**

Production area is expected to fully operate in the **second half of 2021**

PRC Headquarters

Located in Suzhou Dushu Lake High Education Town, with a total floor area of approximately **70,000 sq.m**

Plan to build an R&D centre and a production base, with a production capacity over **30,000L**

Foundation works have been completed; Superstructure works have been commenced and are expected to be completed by **late 2022**

Haikou Production Base



Currently in use for producing clinical drugs

Occupies **4,526 sq.m** with **1,200L** capacity, which is sufficient for clinical and initial marketing needs

Consists of a clean area, a controlled-not-classified (CNC) area, quality control laboratories, etc.

02 Financial Performance

Total Comprehensive Loss



RMB '000

Net Cash Flows Used in Operating Activities



RMB '000

Net Cash Flows Used in Financing Activities



RMB '000

Cash Flows from Investment Activities



RMB '000

R&D Costs



RMB '000

Breakdown of R&D Costs



03 Future Strategies

Strategic Layout

Established a full-spectrum platform across the entire value chain

Entered into a long-term collaboration with D2M Biotherapeutics Limited for the identification of novel drug targets

Well prepared for commercialisation, backed by production facilities and sales team to be assembled

Commercialisation

Expect to **build up a sales team by 2021**, covering a majority of provinces and municipalities in China

To begin implementing sales and marketing strategies with an initial focus on the commercialisation of SM03

Actively exploring and identifying opportunities for collaboration or partnership, including but not limited to licencing in or licencing out

2020 — 2021 — ...

Albeit uncertainties associated with COVID-19, we expect to build up our sales team by 2021.

Future Strategies

We are committed to establishing ourselves as a global leader in the innovation of therapeutics for immunological diseases.



"Since establishment, SinoMab has always been pursuing the mission of discovering and developing novel drug targets, which has never been forgotten. In the future, we will make the utmost effort to advance the medical industry together with all parties, to fulfil our promises to patients, Shareholders and society."

Chairman, Executive Director and Chief Executive Officer
Dr. Shui On LEUNG